. 2023 May 6;37(5):675–684. doi: 10.1007/s40259-023-00601-w

Table 1.

Interrupted time-series analysis of monoclonal antibodies and antivirals drugs use across two different time segments: pre- and post-end of Delta variant, in England and Italy

	Country	β^b	Prevalence ratio	95% CI	p-Value	p-Value (Italy versus England)
Bamlaniviamb/etesevimab^a	Italy	–	–	–	–	–
Bamlaniviamb/etesevimab^a	England	–	–	–	–	–
Sotrovimab	Italy	0.080	1.083	1.052–1.116	< 0.001	< 0.001
Sotrovimab	England	1.491	4.445	4.322–4.572	< 0.001	< 0.001
Tixagevimab/cilgavimab^a	Italy	–	–	–	–	–
Tixagevimab/cilgavimab^a	England	–	–	–	–	–
Casirivimab/imdevimab	Italy	−1.630	0.195	0.180–0.212	< 0.001	–
Casirivimab/imdevimab	England^a	–	–	–	–	–
Remdesivir	Italy	0.963	2.619	2.521–2.718	< 0.001	< 0.001
Remdesivir	England	2.228	9.281	6.896–12.553	< 0.001	< 0.001
Molnupiravir	Italy	0.931	2.537	2.479–2.596	< 0.001	< 0.001
Molnupiravir	England	1.448	4.254	4.100–4.410	< 0.001	< 0.001
Nirmatrelvir/ritonavir	Italy	2.210	9.115	8.846–9.393	< 0.001	0.440
Nirmatrelvir/ritonavir	England	2.220	9.207	8.935–9.487	0.010	0.440

CI confidence interval

^aNot applicable

^bLevel change parameter